Stryker Co. (NYSE:SYK) Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp reduced its position in shares of Stryker Co. (NYSE:SYK) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 328,220 shares of the medical technology company’s stock after selling 6,903 shares during the quarter. Stryker comprises 0.8% of Boston Trust Walden Corp’s portfolio, making the stock its 25th largest holding. Boston Trust Walden Corp owned about 0.09% of Stryker worth $118,176,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of SYK. Zhang Financial LLC raised its position in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after acquiring an additional 40,784 shares in the last quarter. Dale Q Rice Investment Management Ltd bought a new stake in shares of Stryker in the 4th quarter worth approximately $587,000. Berkshire Bank raised its holdings in shares of Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock worth $3,056,000 after purchasing an additional 1,030 shares in the last quarter. PFW Advisors LLC acquired a new stake in Stryker during the fourth quarter valued at approximately $1,350,000. Finally, Traynor Capital Management Inc. bought a new stake in Stryker during the fourth quarter worth approximately $324,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SYK. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Truist Financial upped their target price on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday. The Goldman Sachs Group lifted their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research note on Thursday. Stifel Nicolaus upped their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, Wells Fargo & Company lifted their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Stock Up 0.1 %

Shares of Stryker stock opened at $390.90 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $149.02 billion, a price-to-earnings ratio of 50.37, a P/E/G ratio of 2.78 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The stock has a 50-day simple moving average of $376.68 and a 200-day simple moving average of $363.22.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm posted $3.46 earnings per share. On average, equities research analysts expect that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st were issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s dividend payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.